The fraction of heterozygous carriers of potentially disease-associated
ATM variants in our IPT cohort significantly exceeded the expected frequency of heterozygous carriers in the general population of European ancestry, as determined in large epidemiologic studies from Europe and the United States.
31 32 In these, the carrier frequency of pathogenic
ATM alleles in the general population has been estimated at 0.5% to 1%,
31 32 which is statistically significantly different from the same frequency, 8.7% (2 of 23;
P = 0.02), in the IPT cohort. Interestingly, this fraction perfectly correlates with the fraction of Dutch patients with breast cancer who carried AT-causing mutations.
33 The frequency of possibly disease-associated
ATM missense alleles, excluding the common D1853N SNP, is approximately 20% in European breast cancer patients,
34 which is again lower than the analogous fraction (35%, 8 of 23;
P = 0.05) in this study. The association of
ATM missense alleles with cancer has varied between studies. The relatively rare S707P variant (allele frequency, 0.005–0.02)
18 has been (marginally) associated with breast cancer in several studies.
18 19 We detected this variant in 2 of 23 patients in our study, resulting in higher allele frequency (0.043). The overall frequency of P1054R, L1420F, and D1853N variants was not statistically different in breast cancer patients and controls
18 ; however, there was a trend for an association for D1854N homozygotes, P1054R heterozygotes, and node-positive breast cancer patients in the same study.
18